Guillain-Barré syndrome is a rare neurological disorder in which the immune system attacks part of the nervous system.
Among the 12.8 million people who have received Johnson & Johnson’s COVID-19 vaccine in the U.S., about 100 preliminary reports of Guillain-Barré syndrome have emerged.
The FDA and CDC’s response will communicate that while there is a small risk associated with receiving Johnson & Johnson’s COVID-19 vaccine, the benefits outweigh the risks.
Johnson & Johnson said July 12 it is in talks with the FDA and other regulators about the reports of Guillain-Barré syndrome.
“The chance of having this occur is very low, and the rate of reported cases exceeds the background rate by a small degree,” the drugmaker said.
The recent development comes three months after the FDA and CDC recommended the U.S. pause its use of Johnson & Johnson’s COVID-19 vaccine while they reviewed reports of rare but serious blood clots in people who’ve received the shot. The pause was lifted 10 days later, when the agencies decided to resume the shot’s use with a warning label stating the risk of rare but potentially dangerous blood clots.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
